QUANTUM X LABS INC. quarterly report, Q2 FY2017

Business Context and Reporting Period

Company: Emerald Medical Applications Corp. (Note: Input metadata referenced "Quantum X Labs Inc.", but the filing text identifies the registrant as Emerald Medical Applications Corp.)
Reporting Period: Quarterly period ended June 30, 2017 (Form 10-Q).
Business Overview: A digital health startup developing "DermaCompare," a proprietary software for derma imaging and analytics to assist in skin cancer screening. The company is in the development stage with no commercial revenue to date.

Key Financial Metrics

Metric Six Months Ended June 30, 2017 Six Months Ended June 30, 2016
Revenue $0 $0
Net Loss $(1,694,608) $(3,088,204)
Operating Expenses $1,032,427 $3,115,751
Finance Expense $(662,181) $27,547 (Income)
Cash and Cash Equivalents (End of Period) $14,110 $274,562
Total Current Liabilities $2,042,931 $958,197
Working Capital $(2,025,163) $(944,355)

Liquidity: The company reported negative working capital of approximately $2.0 million. Cash flow from operations was negative $511,652, while financing activities provided $526,231 primarily from the sale of common stock.

Material Changes vs. Prior Period

  • Net Loss Reduction: Net loss decreased by approximately $1.4 million compared to the prior year period, primarily due to a significant reduction in General and Administrative (G&A) expenses.
  • G&A Expenses: Dropped from $2.82 million (6 months 2016) to $682,606 (6 months 2017). The prior year included significant merger-related costs and share-based compensation not present in the current period.
  • Finance Costs: Finance income of $27,547 in the prior year turned into an expense of $662,181. This increase is attributed to penalties and liquidation damages recorded under a settlement agreement with convertible note holders (Alpha Anstalt Capital and Chi Squared Capital Inc.).
  • Liabilities: Total current liabilities more than doubled, driven by a new provision of $740,860 for the settlement of convertible notes and an increase in the principal amount of convertible notes.

Outlook, Risks, and Management Commentary

  • Going Concern: The filing includes an explanatory paragraph regarding "going concern." The company has limited capital and requires additional financing (estimated at $1.5 million) to continue operations for the next 12 months.
  • Debt Settlement: In August 2017 (subsequent event), the company settled disputes with note holders by extending maturity dates to 2019 but increasing principal amounts and issuing Series A Convertible Preferred Stock. This resulted in a $740,860 provision recorded in the current period.
  • Revenue Outlook: The company has generated no revenue. Future plans involve selling software licenses to healthcare providers, but commercialization is not yet achieved.
  • Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2017.
  • Risks: Risks include the inability to raise additional capital, dependence on successful R&D outcomes, and potential expiration of net operating losses before utilization.

Investor Verification Checklist

  • Cash Runway: Verify the sufficiency of the $14,110 cash balance against the stated need for $1.5 million in additional capital.
  • Debt Obligations: Confirm the terms of the August 2017 settlement agreement regarding the increased principal on convertible notes and the issuance of Series A Preferred Stock.
  • Revenue Generation: Assess the timeline for commercializing the DermaCompare software and securing paying customers.
  • Internal Controls: Review the specific material weaknesses identified in the ineffective disclosure controls.
  • Related Party Transactions: Verify the $88,178 outstanding payable to related parties and the nature of services provided.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.